Nanosonics Ltd
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|&KgtWpK | LOCK|ZT#z | LOCK|@y#p%< |
Nanosonics: Coris Receives US Regulatory Approval
As we anticipated, Nanosonics’ next major product, Coris, has received US regulatory approval. Coris is designed to automate the cleaning of flexible endoscopes, particularly the complex channels prone to biofilm build up. The positive results from a clinical study in June 2024 demonstrate that Coris outperforms manual cleaning in biofilm removal in endoscopes. We foresee a promising future for Coris and forecast its sales to grow to AUD 100 million by fiscal 2034, accounting for 23% of our fiscal 2034 forecast group revenue. Coris underpins about 16% of our fair value estimate.
